PH31051A - Agents for treating substance abuse disorders. - Google Patents

Agents for treating substance abuse disorders.

Info

Publication number
PH31051A
PH31051A PH46084A PH46084A PH31051A PH 31051 A PH31051 A PH 31051A PH 46084 A PH46084 A PH 46084A PH 46084 A PH46084 A PH 46084A PH 31051 A PH31051 A PH 31051A
Authority
PH
Philippines
Prior art keywords
pct
abuse
agents
substance abuse
abuse disorders
Prior art date
Application number
PH46084A
Other languages
English (en)
Inventor
Bjork Anders
Anderson Gunner
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of PH31051A publication Critical patent/PH31051A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
PH46084A 1992-04-21 1993-04-21 Agents for treating substance abuse disorders. PH31051A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201239A SE9201239D0 (sv) 1992-04-21 1992-04-21 Agents for treating substance abuse disorders

Publications (1)

Publication Number Publication Date
PH31051A true PH31051A (en) 1998-02-03

Family

ID=20386004

Family Applications (1)

Application Number Title Priority Date Filing Date
PH46084A PH31051A (en) 1992-04-21 1993-04-21 Agents for treating substance abuse disorders.

Country Status (26)

Country Link
US (1) US5565455A (no)
EP (1) EP0637242B1 (no)
JP (1) JP3245642B2 (no)
KR (1) KR100321319B1 (no)
AT (1) ATE184484T1 (no)
AU (1) AU659941B2 (no)
BG (1) BG62154B1 (no)
BR (1) BR9306361A (no)
CA (1) CA2118512C (no)
CZ (1) CZ281296B6 (no)
DE (1) DE69326459T2 (no)
DK (1) DK0637242T3 (no)
EE (1) EE02974B1 (no)
ES (1) ES2139007T3 (no)
GR (1) GR3032030T3 (no)
HU (1) HU223463B1 (no)
IL (1) IL105449A (no)
NO (2) NO308827B1 (no)
PH (1) PH31051A (no)
RO (1) RO117150B1 (no)
RU (1) RU2126254C1 (no)
SE (1) SE9201239D0 (no)
SK (1) SK279940B6 (no)
UA (1) UA27884C2 (no)
WO (1) WO1993020821A1 (no)
ZA (1) ZA932757B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
SE9601708D0 (sv) 1996-05-06 1996-05-06 Pharmacia Ab Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
KR100607838B1 (ko) 1997-10-27 2006-08-04 뉴로서치 에이/에스 니코틴 작용성 아세틸콜린 수용체상의 콜린 작용성 리간드로서의 호모피페라진 유도체 및 이를 포함하는 약제학적 조성물
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
RU2215527C2 (ru) * 2001-09-28 2003-11-10 Областная наркологическая больница Способ купирования алкогольного абстинентного синдрома, алкогольного делирия, острого алкогольного галлюциноза
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2958694A (en) * 1959-06-22 1960-11-01 Janssen Paul Adriaan Jan 1-(aroylalkyl)-4-(2'-pyridyl) piperazines
US2985657A (en) * 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
US2979508A (en) * 1959-10-12 1961-04-11 Paul A J Janssen Heterocyclic derivatives of 1-phenyl-omega-(piperazine) alkanols
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
US4766215A (en) * 1987-02-27 1988-08-23 American Home Products Corporation Histamine H1 -receptor antagonists
SE8701375D0 (sv) * 1987-04-02 1987-04-02 Leo Ab Novel pyridyl- and pyrimidyl derivatives
US5217987A (en) 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
SE9201239D0 (sv) 1992-04-21
RU2126254C1 (ru) 1999-02-20
CA2118512A1 (en) 1993-10-28
RO117150B1 (ro) 2001-11-30
NO20004169L (no) 1994-10-20
KR100321319B1 (ko) 2002-07-27
IL105449A (en) 1998-02-22
AU659941B2 (en) 1995-06-01
CZ281296B6 (cs) 1996-08-14
WO1993020821A1 (en) 1993-10-28
UA27884C2 (uk) 2000-10-16
SK279940B6 (sk) 1999-06-11
DE69326459D1 (de) 1999-10-21
ES2139007T3 (es) 2000-02-01
NO318461B1 (no) 2005-03-21
US5565455A (en) 1996-10-15
EE02974B1 (et) 1997-04-15
JPH08503449A (ja) 1996-04-16
NO308827B1 (no) 2000-11-06
JP3245642B2 (ja) 2002-01-15
EP0637242B1 (en) 1999-09-15
NO20004169D0 (no) 2000-08-21
HU223463B1 (hu) 2004-07-28
KR950701221A (ko) 1995-03-23
EP0637242A1 (en) 1995-02-08
HU9403020D0 (en) 1994-12-28
DE69326459T2 (de) 2000-03-23
GR3032030T3 (en) 2000-03-31
RU94045866A (ru) 1996-10-20
ATE184484T1 (de) 1999-10-15
NO943977D0 (no) 1994-10-20
SK126994A3 (en) 1995-07-11
AU4043793A (en) 1993-11-18
ZA932757B (en) 1993-10-28
BR9306361A (pt) 1998-06-30
CZ260694A3 (en) 1995-09-13
HUT71420A (en) 1995-11-28
DK0637242T3 (da) 2000-03-27
CA2118512C (en) 2004-07-27
BG62154B1 (bg) 1999-04-30
IL105449A0 (en) 1993-08-18
BG99129A (bg) 1995-08-28
NO943977L (no) 1994-10-20

Similar Documents

Publication Publication Date Title
GR3032030T3 (en) Agents for treating substance abuse disorders.
GR3035805T3 (en) New use of diphenylbutylpiperazinecarboxamides in the treatment of substance disorders.
GR3031448T3 (en) Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
BG97678A (en) Beta -carotene and/or vitamin e therapy for inhibition of major vascular events
Coccaro Psychopharmacological studies in patients with personality disorders: Review and perspective.
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
James Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers
ZA925146B (en) Pharmaceutical agent for treatment of withdrawal symptoms.
MD1716C2 (ro) Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
NO943293L (no) Anvendelse av et medikament ved avvenning mot röyk
Baughman The safety record of buspirone in generalized anxiety disorder.
DE69307705D1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung
King AZT delta study: major European/Australian study finds combinations better than AZT alone
KR940003550A (ko) 노인성 치매 예방 및 치료방법
KR880012231A (ko) 스테로이드의 용도